Skip to content
Peptigraph home

Sermorelin and Tirzepatide Together: What Is Known

Sermorelin and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[18]Growth hormoneGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[19]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Sermorelin is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component

Side by side

Showing 11 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldSermorelinTirzepatide
ClassGHRH analogGLP-1 / GIP dual agonist
Also called—tirz, tirze, Mounjaro, Zepbound
CategoryGrowth hormoneGLP-1 & metabolic
FDA statusCompounded by prescriptionFDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised6 human (1 randomized or controlled) of 9 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)
Related tools

Sermorelin vs Tirzepatide

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Sermorelin: paediatric and small adult studies, no current label

One adult study gave healthy older men nightly subcutaneous self-injections of GHRH for 6 weeks.[9]

In that older-men study, GHRH treatment did not change weight, BMI, waist-to-hip ratio or DEXA fat and muscle measures.[9]

Sermorelin has no currently marketed FDA-approved product; the only record is Geref, listed as discontinued.[21]

Tirzepatide: label interactions that matter for any add-on

The Zepbound label says tirzepatide delays gastric emptying and may affect the absorption of concomitantly administered oral medications.[22]

The label also flags that tirzepatide lowers blood glucose and advises considering a lower dose of insulin or sulfonylureas when starting it.[22]

It warns patients on oral hormonal contraceptives to change method around starting and dose escalation.[22]

No trial of the pair

A PubMed title and abstract search on 2 Oct 2026 for sermorelin with tirzepatide returned 0 records.

Calculated from pubmed query (sermorelin[tiab] OR Geref[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); records matched 0; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

The tesamorelin label, for a drug in the same GHRH class, reports elevated HbA1c (6.5% or higher) in 5% of Egrifta-treated patients against 1% on placebo through Week 26.[23]

In a small earlier trial of GHRH in healthy older men, treatment did not affect fasting glucose, blood pressure or routine chemistry.[7]

Common questions

Can you take sermorelin with tirzepatide?

No study has tested the combination, and sermorelin has no current approved label to check for interactions.[21]

Does tirzepatide affect sermorelin absorption?

The tirzepatide label cites slower gastric emptying as an issue for oral medicines. Sermorelin is given by injection, and no interaction study is cited.[22]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  6. 6Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  7. 7Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  8. 8Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  9. 9Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  14. 14Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  15. 15Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  16. 16Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  17. 17PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  19. 19Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  20. 20PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  21. 21Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  22. 22ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  23. 23EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.